CureVac (CVAC) began trading on the Nasdaq on Fri 14 Aug 2020

CureVac priced 13.3 mln share IPO at $16, the high end of the $14-$16 expected price range
CureVac BV raised $213 million in its initial public offering (IPO) in New York on Thursday, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the coronavirus.

• The big draw is its mRNA COVID-19 vaccine candidate, currently in Phase 1 development. Topline data should be available next quarter.
• Lead program is CV8102, also in Phase 1 development, for the treatment of four types of solid tumors.
• Earlier this year, CureVac tapped investors, including the German government and GSK, for $640M to support its work against the coronavirus and other diseases.